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Abstract
Biobanking is now a key discipline in cancer research and its infrastructure. This helps accelerate 
translational research and is typically pathology-led. To use biobanked tissues to best effect, sample 
quality is paramount, and biobanks have a responsibility to ensure this is achieved. In 2016, the 
National Cancer Research Institute (NCRI) established the Cellular & Molecular Pathology initiative 
(CM-Path), which aims to re-invigorate UK academic pathology in the UK. One of the goals of the 
CM-Path biobanking subgroup group was to create a Biobanking Sample Quality Improvement Tool. 
The tool is a confidential self-assessment of current practices within a biobank, focusing on tissue 
quality and identifying areas with the potential for improvement. Here we describe the development 
and implementation of this tool and discuss what it can offer to the cancer biobanking community.
Introduction
Good quality tissue samples are essential to drive translational research and can be obtained from 
biobanks. Biobanking has gradually evolved from ‘private’ collections, usually initiated by academics 
or commercial companies with interests in specific disease types, into a discipline in its own right 
enabling translational research allied to laboratory and clinical investigations, or as an adjunct to 
clinical trials. Whilst requiring engagement by all members of the multi-disciplinary team, 
pathologists remain central to this, and best practice biobanking, at least in cancer, should have 
input from appropriately skilled pathologists.
Biobanks now exist across the world. Many operate according to strict Standard Operating 
Procedures (SOPs) with global (ISBER (International Society for Biological and Environmental 
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Repositories); https://www.isber.org/), European (BBMRI-ERIC (Biobanking and BioMolecular 
Resources Research Infrastructure-European Research Infrastructure Consortium);  
http://www.bbmri-eric.eu/) and national (CTRNet; Canadian Tissue Repository Network; 
http://www.ctrnet.ca/) frameworks developed. The National Cancer Research Institute (NCRI), 
established as a UK-wide partnership between cancer research funders, recognised the need for 
better harmonisation and greater coordination between biobanks and established the 
Confederation of Cancer Biobanks (CCB; https://cmpath.ncri.org.uk/ccb/) in 2006. The goal of the 
CCB was to share best practice and raise awareness of existing sample collections with researchers, 
so that tissues donated by patients could be used to best effects. In 2016 the (NCRI) Cellular 
Molecular Pathology (CM-Path) initiative (https://cmpath.ncri.org.uk/) was established as a means 
of strengthening the academic pathology base across the UK to enhance pathology-led research (1). 
Within this structure a separate biobanki g sub-group was established. Subsequently, the CCB was 
incorporated into CM-Path with CM-Path continuing the work initiated by the CCB.
Issues with tissue samples for cancer research may relate to quality and quantity.  It is recognised 
that, following excision from patients, tissues are subject to widespread variability in conditions 
encountered during their journey to the biobank and onwards to research laboratories, at both the 
pre- and post-acquisition stage. Variables like ischaemic times, sample handling, storage, distribution 
etc., may adversely affect tissue quality, potentially impacting on data generated. Several 
publications have described degradation of protein epitopes because of fixation delay, with 
phosphoproteins particularly susceptible (2-4). Sometimes it may be necessary to obtain tissue from 
multiple biobanks in order to accrue sufficient numbers of samples to capture the full disease 
spectrum. Registries of biobanks exist in the UK (https://www.biobankinguk.org/) and Europe, with 
the BBMRI-ERIC Directory 2.0 listing > 60 million samples from 515 biobanks or individual collections 
(5), which can help researchers identify and source suitable tissues. However, unless biobanks are 
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working to equivalent standards and quality management, variability in tissue collection protocols 
may compromise research results, which may raise questions regarding sample consistency (6, 7). 
The old adage “garbage in garbage out” applies acutely to biobanks.  To mitigate this, the 
Biospecimen Reporting for Improved Study Quality (BRISQ) guidelines were established, providing 
information on consistency of collection, processing and storage of human tissues, with an emphasis 
how to report these in research publications (8), however this does not appear to be adopted 
widely.
One of the goals of the CM-Path biobanking subgroup was to develop, pilot and implement a 
Biobanking Sample Quality Improvement Tool to help biobanks identify factors which could improve 
tissue quality, and consequently, data output, for researchers. Here we describe this tool and discuss 
what it can offer to the biobanking community.
Methods
Development
Through various Working Groups, the CCB had previously established and agreed a set of quality 
standards (“Guiding Principles”) to be adopted by biobank staff, to provide assurance on the value of 
the samples and data that they held (http://cmpath.ncri.org.uk/wp-content/uploads/2019/06/CCB-
Guiding-Principles-v7.pdf). These were used as the basis for developing the Biobanking Sample 
Quality Improvement Tool. An initial scoping phase involved phone consultations between the 
project coordinator (HF) and various specialists in biobanking (named in the acknowledgments) to 
determine the need for such a tool. Subsequently, each member of the CM-Path biobanking 
subgroup (AH, JH, VS, GT), all biobankers with significant experience in conducting and supporting 
translational cancer research across different tumour types were assigned to develop a specific 
section of the Biobanking Sample Quality Improvement Tool. Patient input was provided by RT. They 
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worked closely with HF through phone consultations and email to develop a series of questions. 
Subsequently, these data were shared with other members of the CM-Path biobanking subgroup 
and refined further through an iterative process via fortnightly teleconferences and email. Links to 
relevant literature were identified and incorporated into the tool to assist end users. The tool was 
designed, such that upon completion, a report could be generated to flag up areas of attention the 
biobank staff may wish to consider. Once agreement was reached, this information was used to 
populate the Biobanking Sample Quality Improvement ToolBiobanking Self Improvement Tool. To 
promote ease of use and of access, we designed the Biobanking Self Improvement Tool using 
Microsoft Excel, a commonly used software package with widespread availability. The tool can be 
downloaded, free of charge, at: http://bit.ly/CM-Path_biobanking. The dashboard for the tool is 
shown in Figure 1.
Pilot phase
The tool was piloted across four UK biobanks, selected to provide diversity in collections and funding 
models as well as a good geographical spread: Greater Glasgow & Clyde Biorepository (multiple 
cancers; government funded; Scotland), Leeds Breast Cancer Now Tissue Bank (breast cancer tissues; 
charity funded) and Multidisciplinary Research Tissue Bank (mainly renal, colorectal and 
gynaecological cancers; charity, research council funded; North of England) and Southampton Tissue 
Bank (multiple cancers; charity, research council funded; South of England). Opinions were sought 
from biobank staff at these centres on the usability of the tool and suggestions for improvements 
encouraged prior to its launch to the biobanking community. Participants who piloted the tool were 
independent, but they were located at the sites of the creators of the tool.
Post-launch phase
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After the tool had been operational for several months, opinions were sought from users on general 
impressions, any technical difficulties, if the tool highlighted areas in end user’s organisation that 
required attention, suggestion of areas for improvement and who would benefit from using the tool. 
Results
Pilot phase
Initial general feedback at the piloting phase was encouraging: 
“Overall this looks like a really useful tool. It was straightforward to use, and I found the links to 
research and example forms useful.”
“The CM-Path biobanking tool is very professionally laid out and easy to use. The tabs are useful and 
logical.”
 “Easy to navigate around. Bold bright colours and nice layout.”
Participants in the pilot gave more specific feedback, highlighting several operational issues with the 
tool to ensure that the whole spreadsheet was functioning as it should. For example, ensuring drop 
down boxes were functional and that the correct text came up relating to the right question. They 
also checked the wording to make sure this didn’t across as confrontational, judgemental or off-
putting to ensure it was being used purely as an educational tool. These were addressed prior to 
launch. Participants felt the tool would be valuable for internal auditing of established biobanks and 
useful when setting up new biobanks to ensure SOPs were in place and that the correct guidelines 
were being followed. They also highlighted its use for all biobank staff, as it could provide everyone 
with confidence in quality of the samples they have collected and stored for research.
Launch
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The Biobanking Sample Quality Improvement Tool The Biobanking Self Improvement Tool was 
launched to the UK biobanking community at a workshop held in Leeds, England on 16 May 2018. 
Upon clicking on http://bit.ly/CM-Path_biobanking  users are taken to the CM-Path home page 
within NCRI. To download the tool, users are asked to enter name, email address and organisation 
with a yes/no option for future contact regarding providing feedback on the tool. A link to copy and 
paste into a browser then appears and the tool is downloaded as a zip file. Once unzipped, this 
opens as an Excel spreadsheet (Figure 1).  Users may access topics related to sample acquisition, 
storage, transport and standard operating procedures, either as tabs or radio buttons. When these 
are clicked, a series of questions related to each topic appear. These are completed by selecting the 
appropriate answer from a dropdown menu. After each response a commentary and/or evidence 
appears explaining why the subject of the question is important with respect to the quality of 
samples being stored, often linking to additional reading. Where answers indicate there could be 
room for improvement, suggestions can be found in the tab ‘flagged areas’ and the ‘links’ tab offers 
relevant information from other sources. These are tailored to the responses provided by users. By 1 
November 2019 the tool had been downloaded 81 times from 12 countries (UK x40, France x2, once 
each from Austria, Belgium, Denmark, India, Ireland, Saudi Arabia, Ukraine). There were 32 
downloads from unknown locations or countries as the people downloading did not disclose their 
organisation or location. At least five downloads were from industry, one pharma company, several 
charities and university/NHS hospitals across the UK and beyond. 
Discussion
As we move towards personalised approaches to medicine, which requires access to high quality 
human tissue samples, improvements in biobanking are very much on the agenda to help ensure 
that sample quality meets the expectations of researchers.  
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There have been international efforts towards biobanking self-improvement. The Canadian Tissue 
Repository Network (CTRNet) developed and implemented a set of required operational standards, 
which all biobanks in their network had to adhere to in order to gain CTRNet certification (6). This 
was endorsed by ISBER (7). More recently a biobank certification scheme has been developed in 
Australia (9). This took the operational costs of running a biobank into consideration and set 
guidelines for best practice management of collected materials in biobanks and benchmarks for 
subsequent certification. The Australian model also accounted for resources required to obtain and 
maintain certification, with biobanks employing the highest numbers of staff reporting the lowest 
anticipated costs in gaining and maintaining this (9).
While these are undoubtedly positive developments, development and implementation of an 
informative, user-friendly tool designed to support the improved quality of samples donated to UK 
biobanks was lacking. Our tool has bridged this gap. Feedback from the community has been positive 
and uptake has been steady with 81 downloads since its launch. Interestingly this has included users 
from beyond the UK, with downloads from as far afield as Ukraine and Saudi Arabia, demonstrating 
a wider reach.  A frequent comment was how useful the tool would be for new members of staff or 
for those who were new to the biobanking field as well as offering a checklist to ensure that 
biobanks are covering important aspects of sample quality and ensuring robust SOPs are in place 
following the correct guidelines and science.  
We acknowledge that other tools are available which address sample quality in biobanks, notably 
ISBER, College of American Pathologists (CAP) and BBMRI-ERIC. ISBER offers suite of tools on their 
website (https://www.isber.org/) but much of this is restricted to members only, notably their Self-
Assessment Tool. The ISBER website also signposts freely available information e.g. 
https://www.findmyassay.com, which provides a guide to identify if previously collected tissues are 
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fit for purpose for a range of experiments methods. CAPs Biorepository Accreditation Programme 
(10) employs peer-based inspections to accredited biobanks enrolled on their programme. 
Accreditation is over 3 years, obtained through application, annual enrolment fee and submission of 
information on the activities of the biobank, followed by on-site peer inspection in the first year, 
then self-inspection plus CAP desk assessment in the second and third years. BBMRI-ERIC’s ISO 
20387:2018 Biotechnology – Biobanking - General requirements for biobanking is a comprehensive 
document, conforming to ISO standards, however it is behind a paywall of $160 / €150.  Importantly,  
our the tool is free and accessible for everyone, using a commonly used Microsoft platform which 
builds on areas already covered by current relevant UK legislation set by the Human Tissue Authority 
and Healthcare Improvement Scotland. It offers an internal self-assessment of current practices, 
focusing on tissue quality and identifying areas which could be improved and although developed in 
the UK, has applicability to biobanks everywhere.   
 
The focus here has been on the quality of tissue samples within biobanks, however we recognise the 
need for good quality data to accompany these samples to derive most benefit from them. 
Informatics and data management aspects of biobanking are discussed elsewhere (11-14).
In summary, the CM-Path Biobanking Sample Quality Improvement Tool offers a free and 
confidential way for biobanks to work towards improving their standards. We encourage the 
community to view this tool and to consider implementing this into their workstreams.
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Table 1
Summary of points raised by users of the CM-Path Biobanking Sample Quality Improvement Tool
Questions Responses
General comments  Using the different tabs and answering the questions is 
very straightforward
 Covers a wide range of specific questions that we should 
all be asking regarding sample collection and processing
Value of the tool  Good for internal auditing of banks
 Useful when setting up new sites/ new tissue banks:  
making sure all SOPs are in place and are following the 
correct guidelines and science
 Checklist to ensure that banks are covering every aspect 
of sample quality
 Following set standards could help inform cost recovery
 Very useful for anyone considering setting up a bank
 Useful for established banks who want to tighten up 
processes
Ease of use  Very easy and quick to use (around 20 mins)
 Self-explanatory
 Helpful that can jump forward to certain areas according 
to area of interest or specific SOPs 
What specific areas of the tool 
are important? 
 All aspects of the tool are important
 Flagged areas are most important as these indicate what 
could be changed to improve 
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 Reminder to ensure that ischemic times, freeze thaw 
cycles and time in fixative are all recorded are 
particularly important
 Lot of useful links provided for further exploration
What areas of quality could 
potentially be improved by 
use of the tool? 
 Sample quality, particularly for certain techniques
 Tool offers ability to evidence quality of samples and 
processes
Who in the biobank would 
benefit from the tool? 
 All personnel, as it provides everyone with 
confidence/knowledge of the quality of samples they 
have stored and are giving out
 Manager/head of biobank would be able use it for audit 
and checking status of SOPs
 Excellent for new staff to help understand why specific 
tasks are performed and recorded
 Add to the list of resources for new staff joining the 
biobank so everyone is on the same page
How could the tool be 
improved?
 Better if the questions had more options as not 
everything has binary answers
 Consider sections on collection of blood derivatives
 Revisit the tool periodically to keep it updated as new 
methods emerge and its use evolves
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Dashboard for the Biobanking Self Improvement Tool.  Users are presented with a series of tabs on 
topics related to sample acquisition, storage, transport, and standard operating procedures, which 
expand to show a series of questions related to the topic. Once completed, suggestions for 
improvement can be found in the tab ‘flagged areas’ and the ‘links’ tab offers relevant information 
from other sources.
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